| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3349039 | The Egyptian Rheumatologist | 2014 | 5 Pages |
Aim of the workTo determine the epidemiological, clinical, paraclinical and therapeutic profile of bone metastases of prostate cancer.Patients and methodsThis was the study of a series of cases of bone metastases of prostate cancer.ResultsFifty-eight of 2881 patients (2%) admitted to the Rheumatology department during 21 years suffered from a bone metastasis of prostate cancer. The average age at admission was 64.27 ± 8.9 years while the disease duration was 28.43 ± 44.16 months. Prostate cancer was known in 27% of cases before the metastasis and the metastasis was revealing in 73% of cases. The average time between the diagnosis of prostate cancer and the development of metastasis was 5.4 ± 3.67 years in 27% of the cases. The main manifestations of patients with bone metastases were alteration of general condition (81.03%), inflammatory bone pain (75.86%), voiding disorders (58.62%) and spinal cord compression (36.20%). The spine was the main area of pain (89.65%). An osteosclerosis was the most observed radiological lesion (63.79%). The prostate specific antigen average was 301.87 ± 738.23 ng/ml. Histopathological examination was performed in 18 patients and confirmed adenocarcinoma of the prostate. Hormone therapy, mainly by anti-androgens (86.20%), surgical treatment (32.75%) and orthopedic treatment (29.31%) was administered in our patients. A severe anemia caused the death of seven patients (12.06%) during hospitalization.ConclusionDiagnosis of cancer of the prostate is late and takes place in the majority of cases at the stage of metastasis.
